ArticleStem cell research & therapy2026
Distinct decidualization and senomorphic responses in endometrial vs. menstrual blood stem/stromal cells: implications for reproductive therapies.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDecidualization, the process of endometrial stem/stromal cell (EnSCs) differentiation, is essential for embryo implantation and pregnancy maintenance. Menstrual blood-derived stem/stromal cells (MenSCs), although often considered as surrogates of EnSCs, represent a distinct population. Pharmacologic modulation of cellular senescence using senomorphics has emerged as a promising strategy in reproductive medicine. This study investigates the decidualization capacity of EnSCs and MenSCs and evaluates how senomorphic agents influence their senescence, metabolic profile, and inflammatory response.
methodsPrimary EnSCs and MenSCs were isolated, characterized, and subjected to in vitro decidualization using standardized protocols. Cells were classified as well-decidualized (WD) or poorly-decidualized (PD) based on the extent of decidualization. Six senomorphic compounds were applied before and during decidualization. Senescence-associated β-galactosidase activity, IL-6 secretion, glycolytic intermediates, and global metabolomic changes were assessed before and after treatment with senomorphics.
resultsMenSCs exhibited accelerated but limited and prolonged decidualization capacity compared to EnSCs. Metabolic reprogramming in EnSCs at day 6 resembled that of MenSCs at day 3. Decidualization induced differential changes in glycolysis-related metabolites, senescence markers, and IL-6, especially in PD cells. Treatment with six senomorphics modulated these effects in a context-dependent manner. Exposure during decidualization increased senescence in both WD and PD sources, whereas pretreatment increased senescence in WD EnSCs but decreased it in PD EnSCs. Notably, senomorphics shifted the metabolomic profile of PD EnSCs toward a WD-like state.
conclusionsEnSCs and MenSCs differ in decidualization dynamics, metabolism, and response to senomorphic modulation. Senomorphics may be strategically employed to reduce senescence in patients with impaired endometrial decidualization, offering therapeutic potential in reproductive pharmacology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.